Related Experiment Video
Updated: Jul 10, 2026
08:27
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
Rivastigmine for Alzheimer's disease
Abhilash K Desai1, George T Grossberg
1Alzheimer's Center of Excellence, Saint Louis University School of Medicine, 3211 E Northshore Boulavard, #157, Appleton, WI 54915, USA. abhilash.desai@thedacare.org
Expert Review of Neurotherapeutics
|September 16, 2005
Summary
Rivastigmine, a cholinesterase inhibitor, effectively treats Alzheimer's disease symptoms. Early and continuous treatment maximizes cognitive and functional benefits, with manageable side effects.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease is a leading cause of dementia, presenting significant challenges.
- Rivastigmine is an approved treatment for mild-to-moderate Alzheimer's disease.
Purpose of the Study:
- To review the efficacy and safety of rivastigmine in Alzheimer's disease.
- To explore its benefits in various dementia types and symptom domains.
Main Methods:
- Analysis of randomized, double-blind, placebo-controlled trials.
- Review of observational data on long-term and broader effects.
Main Results:
- Rivastigmine shows beneficial effects on cognition and global functioning compared to placebo.
- Benefits may extend to 5 years, advanced stages, daily living, and behavioral symptoms.
- Effective for related dementias like Lewy body and Parkinson's disease dementia.
Conclusions:
- Early and sustained rivastigmine treatment enhances benefits in Alzheimer's disease.
- Gastrointestinal side effects can be mitigated through dose titration and administration with meals.
- Optimal dosing ranges from 6-12 mg/day twice daily for maximum benefit.
Related Concept Videos
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...